GlassScriptPhysician profile
Ann M Weiss
NPI 1013094820
$412.70
in general payments reported to CMS, 2019-2025
14 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $49.91 · 2024: $184 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $412.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $49.20 | 2023-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $41.31 | 2024-2025 | |
| Dexcom, INC. | $39.85 | 2023-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $39.25 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $38.69 | 2025 | Symbravo |
| Edwards Lifesciences Corporation | $37.38 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novo Nordisk INC | $36.24 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.96 | 2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $25.26 | 2025 | Recorlev |
| Abbvie INC. | $18.56 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.52 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $16.45 | 2024 | Spravato |
| Sanofi-Aventis U.S. LLC | $14.06 | 2025 | |
| Lilly USA, LLC | $13.97 | 2024 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.